{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:36:16Z","timestamp":1780328176928,"version":"3.54.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The advent of new biologic agents in recent years has increased treatment options for patients with psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the prescribing and switching patterns of biologic agents used for psoriasis in Malaysia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were obtained from the Malaysian Psoriasis Registry from January 2011 to September 2022. All patients treated with biologic agents were included. Those with at least two entries were selected for subgroup analysis to evaluate switching patterns. \u2018Continuous therapy\u2019 was defined as those who continued with the same biologic in the subsequent follow-up, whereas those who switched to another type of biologic were defined as \u2018switching therapy\u2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 25 468 patients, 555 (2.2%) received at least 1 biologic agent. The mean age of patients on biologics was 42.6\u2005years, with a male-to-female ratio of 1 : 0.8. Of 645 biologic prescriptions, secukinumab was the most common (37.8%), followed by ustekinumab (27.9%), adalimumab (18.3%) and guselkumab (4.5%). Etanercept had the longest mean usage duration at 46.2\u2005months. Eighty patients (14.4%) had their biologic agent switched. The most frequent switch pattern was from anti-interleukin (IL)-12\/23 to anti-IL-17 (20 of 80, 25%), followed by tumour necrosis factor inhibitors to either anti-IL-17 (13 of 80, 16%) or anti-12\/23 (11 of 80, 14%). Anti-IL-17 was the preferred agent on switching (37 of 80, 46%). Primary and secondary lack of efficacy were the most common reasons for switching (46% and 25%, respectively). Concurrent systemic therapy was reported in 21.6% of cases (120 of 555). Of these, 76.6% (92 of 120) had received methotrexate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Up to 2% of the patients with psoriasis received treatment with biologics. Anti-IL-17 was the preferred first- and second-line biologic agent used in Malaysia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llaf496","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T12:50:05Z","timestamp":1762692605000},"page":"435-441","source":"Crossref","is-referenced-by-count":1,"title":["Prescribing and switching patterns of biologic therapy in patients with psoriasis: real-world experience"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5487-8570","authenticated-orcid":false,"given":"Chai Har","family":"Loo","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital Pulau Pinang , Georgetown, Penang ,","place":["Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suganthi","family":"Thevarajah","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Kuala Lumpur , Kuala Lumpur ,","place":["Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Moon","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Kuala Lumpur , Kuala Lumpur ,","place":["Malaysia"]},{"name":"Department of Dermatology, Sarawak General, Kuching , Sarawak ,","place":["Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suganthy","family":"Robinson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Kuala Lumpur , Kuala Lumpur ,","place":["Malaysia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"2026022406173513300_llaf496-B1","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1038\/jid.2015.296","article-title":"Psoriasis in the US Medicare population: prevalence, treatment and factors associated with biologic use","volume":"135","author":"Takeshita","year":"2015","journal-title":"J invest Dermatol"},{"key":"2026022406173513300_llaf496-B2","first-page":"39","article-title":"Biologic treatments of psoriasis: an update for the clinician","volume":"15","author":"Brownstone","year":"2021","journal-title":"Biologics"},{"key":"2026022406173513300_llaf496-B3","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2147\/CEOR.S147558","article-title":"Biological therapy utilization, switching and cost among patients with psoriasis: retrospective analysis of administrative databases in Southern Italy","volume":"9","author":"Guerriero","year":"2017","journal-title":"Clinicoecon Outcomes Res"},{"key":"2026022406173513300_llaf496-B4","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1111\/jdv.18409","article-title":"Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ","volume":"36","author":"Curmin","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026022406173513300_llaf496-B5","author":"Ministry of Health Malaysia"},{"key":"2026022406173513300_llaf496-B6","doi-asserted-by":"crossref","first-page":"6799","DOI":"10.3390\/ijerph19116799","article-title":"Use of biological drugs for psoriasis: a drug-utilization study using Tuscan Administrative Databanks","volume":"19","author":"Giometto","year":"2022","journal-title":"Int J Environ Res Publ Health"},{"key":"2026022406173513300_llaf496-B7","doi-asserted-by":"crossref","first-page":"2200870","DOI":"10.1080\/09546634.2023.2200870","article-title":"Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States","volume":"34","author":"Armstrong","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"2026022406173513300_llaf496-B8","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/1346-8138.13860","article-title":"Switching of biologics in psoriasis: reasons and results","volume":"44","author":"Honda","year":"2017","journal-title":"J Dermatol"},{"key":"2026022406173513300_llaf496-B9","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.jaad.2016.01.048","article-title":"Biologic therapy adherence, discontinuation, switching and restarting among patients with psoriasis in the US Medicare population","volume":"74","author":"Doshi","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2026022406173513300_llaf496-B10","doi-asserted-by":"crossref","first-page":"2176708","DOI":"10.1080\/09546634.2023.2176708","article-title":"Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies","volume":"34","author":"Thai","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"2026022406173513300_llaf496-B11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40259-016-0209-y","article-title":"Regional differences in the prescription of biologics for psoriasis in Sweden: a register-based study of 4168 patients","volume":"31","author":"Calara","year":"2017","journal-title":"BioDrugs"},{"key":"2026022406173513300_llaf496-B12","first-page":"745","article-title":"Prescribing patterns associated with biologic therapies for Psoriasis from a United States medical records database","volume":"18","author":"Noe","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"2026022406173513300_llaf496-B13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/1346-8138.16214","article-title":"Real-world, long-term treatment patterns of commonly used biologics in Canadian patients with moderate-to-severe chronic plaque psoriasis","volume":"49","author":"Gooderham","year":"2022","journal-title":"J Dermatol"},{"key":"2026022406173513300_llaf496-B14","first-page":"230","article-title":"Biological retention rates, the reasons of switching, and prognostic factors in patients with psoriasis treated biologics","volume":"45","author":"Tokuyama","year":"2020","journal-title":"Tokai J Exp Clin Med"},{"key":"2026022406173513300_llaf496-B15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1346-8138.2012.01679.x","article-title":"Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis","volume":"40","author":"Takahashi","year":"2013","journal-title":"J Dermatol"},{"key":"2026022406173513300_llaf496-B16","first-page":"1","article-title":"Biologics in psoriasis: updated perspectives on long-term safety and risk management","volume":"12","author":"Al-Janabi","year":"2022","journal-title":"Psoriasis (Auckl)"},{"key":"2026022406173513300_llaf496-B17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","article-title":"Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data","volume":"21","author":"Deodhar","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2026022406173513300_llaf496-B18","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1080\/09546634.2022.2095328","article-title":"Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders","volume":"33","author":"Strober","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2026022406173513300_llaf496-B19","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo-and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2026022406173513300_llaf496-B20","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMVent): a randomized, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"2026022406173513300_llaf496-B21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/bjd.18623","article-title":"Secukinumab for patients failing previous tumour necrosis factor-\u03b1 inhibitor therapy: results of a randomized open-label study (SIGNATURE)","volume":"183","author":"Warren","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026022406173513300_llaf496-B22","doi-asserted-by":"crossref","first-page":"e12793","DOI":"10.1111\/dth.12793","article-title":"When IL-17 inhibitors fail real-life evidence to switch from secukinumab to adalimumab or ustekinumab","volume":"32","author":"Damiani","year":"2019","journal-title":"Dermatol Ther"},{"key":"2026022406173513300_llaf496-B23","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jaad.2013.10.019","article-title":"Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry","volume":"70","author":"Piaserico","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2026022406173513300_llaf496-B24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jaad.2009.08.040","article-title":"Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept","volume":"63","author":"Bissonnette","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"2026022406173513300_llaf496-B25","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2133.2010.09950.x","article-title":"Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept","volume":"163","author":"Van L\u00fcmig","year":"2010","journal-title":"Br J Dermatol"},{"key":"2026022406173513300_llaf496-B26","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jaad.2011.10.020","article-title":"The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study","volume":"67","author":"Gottlieb","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2026022406173513300_llaf496-B27","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1111\/jdv.15100","article-title":"Biologic switching between interleukin 17A antagonists secukinumab and ixekizumab: a 12-week, multicenter, retrospective study","volume":"33","author":"Georgakopoulos","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026022406173513300_llaf496-B28","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/bjd.17580","article-title":"Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience","volume":"180","author":"Conti","year":"2019","journal-title":"Br J Dermatol"},{"key":"2026022406173513300_llaf496-B29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00403-019-01907-y","article-title":"Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study","volume":"311","author":"Gasslitter","year":"2019","journal-title":"Arch Dermatol Res"},{"key":"2026022406173513300_llaf496-B30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/17512433.2020.1767590","article-title":"Switching biologics in psoriasis\u00a0\u2013\u200c\u00a0practical guidance and evidence to support","volume":"13","author":"Tsai","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2026022406173513300_llaf496-B31","doi-asserted-by":"crossref","first-page":"adv00712","DOI":"10.2340\/actadv.v102.206","article-title":"Direct comparison of real-world effectiveness of biologics for psoriasis using absolute and relative Psoriasis Area and Severity Index scores in a prospective multicentre cohort","volume":"102","author":"Van Muijen","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"2026022406173513300_llaf496-B32","doi-asserted-by":"crossref","first-page":"2133531","DOI":"10.1080\/09546634.2022.2133531","article-title":"Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis","volume":"34","author":"Elgaard","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"2026022406173513300_llaf496-B33","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf496\/65268755\/llaf496.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/3\/435\/65268755\/llaf496.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/51\/3\/435\/65268755\/llaf496.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:17:49Z","timestamp":1771931869000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/51\/3\/435\/8320428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,11,11]]},"published-print":{"date-parts":[[2026,2,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf496","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,11,11]]}}}